GlassScriptPhysician profile
Joel M Bernstien
NPI 1710108428
$2,607.68
in general payments reported to CMS, 2019-2025
24 companies · $721 in 2025
The $721 reported for 2025 was more than what 87% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $169 · 2020: $75.78 · 2021: $53.61 · 2022: $388 · 2023: $726 · 2024: $474 · 2025: $721.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,809 · Education: $112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,808.55 |
| Education | $112.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $505.33 | 2019-2025 | |
| Astellas Pharma US INC | $445.67 | 2022-2025 | Veozah, Myrbetriq |
| Hologic Sales and Service, LLC | $237.80 | 2021-2025 | Myosure Tissue Removal Device, Thinprep 2000 Processor, Aptima |
| Evofem Biosciences, INC. | $160.12 | 2023-2025 | Phexxi, Solosec, Phexx |
| Mayne Pharma Commercial LLC | $150.77 | 2022-2025 | |
| Pfizer INC. | $147.44 | 2019-2025 | |
| Exeltis, USA INC. | $138.15 | 2019-2025 | Slynd |
| Organon LLC | $136.07 | 2023-2025 | Nexplanon |
| Biogen, INC. | $119.72 | 2025 | Zurzuvae |
| Sumitomo Pharma America, INC. | $119.63 | 2023-2025 | Myfembree, Gemtesa |
| Abbvie INC. | $119.31 | 2020-2024 | Lo Loestrin Fe, Orilissa |
| Coopersurgical, INC. | $76.63 | 2023-2024 | Endosee |
| Amag Pharmaceuticals, INC. | $38.99 | 2019-2020 | |
| Daiichi Sankyo INC. | $36.51 | 2019 | |
| Therapeuticsmd, INC. | $35.70 | 2019-2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $23.79 | 2025 | Dexcom G6 Transmitter |
| Vertex Pharmaceuticals Incorporated | $23.76 | 2024 | |
| Shield Therapeutics INC | $18.78 | 2023 | Accrufer |
| Agile Therapeutics, INC. | $17.64 | 2024 | Twirla |
| Minerva Surgical, INC | $16.22 | 2024 | |
| Sanofi Pasteur INC. | $15.18 | 2025 | |
| Millicent US INC | $13.35 | 2024 | |
| Allergan, INC. | $11.12 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joel Bernstien listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.